In the year prior to total knee replacement (TKR) surgery, almost one-third of the costs for treatment of arthritis symptoms went toward strategies not recommended by the American Academy of Orthopaedic Surgeons (AAOS), according to new research presented today at the 2017 AAOS Annual Meeting. Costs could decrease by an estimated 30 percent if treatments that are not recommended are no longer utilized.
"As we transition to an era of value based health care, it will be important to consider both the quality of our interventions as well as the cost associated with that care," said study author Nicholas Bedard, MD, an orthopaedic surgeon at the University of Iowa Hospitals & Clinics.
Researchers reviewed Humana Inc. insurance information (both private and Medicare Advantage plans) from 2007 through 2015 on more than 86,000 patients diagnosed with osteoarthritis of the knee, who went on to have TKR within one year. The costs were specifically related to reimbursement for hyaluronic acid (HA) or corticosteroid (CS) injections, physical therapy (PT), braces and wedge insoles, pain medication and non-steroidal anti-inflammatory drugs (NSAIDs). Only three of these treatments -- physical therapy, NSAIDs, and the drug tramadol (short-term for severe pain) -- are recommended in the AAOS clinical practice guideline (CPG): "Non-arthroplasty Treatment of Osteoarthritis of the Knee."
The total costs associated with outpatient knee osteoarthritis was $43,582,648. Among the other findings:
"We hope that research such as this highlights the high prevalence of low-value interventions in the management of knee osteoarthritis and helps to motivate a transition to higher value care," said Dr. Bedard.
Cite This Page: